Research
Investigating the Role of Self-Compassion in MDMA-Assisted Therapy for Social Anxiety Disorder
Open Science Framework – January 01, 2026
Summary
Individuals undergoing MDMA-assisted therapy for social anxiety disorder may experience significant increases in self-compassion, which could enhance mental health outcomes. With a focus on 100 participants, the study aims to track changes in trait self-compassion throughout treatment and assess how state self-compassion during dosing sessions influences these changes. Key areas of evaluation include reductions in social anxiety symptoms, depressive symptoms, and internalized shame. The findings could illuminate the biological mechanisms behind improved wellbeing and functional outcomes in clinical psychology.
Abstract
Self-compassion is theorized to play a central role in promoting mental health and wellbeing, including for individuals with social anxiety disorde...
Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications
Progress in Neuro-Psychopharmacology and Biological Psychiatry – January 01, 2026
Summary
Unlocking the brain's secrets, a pioneering study involving 20 healthy volunteers investigates psilocybin's acute effects on brain activity and cognitive function. Using Electroencephalography (EEG), neurophysiology is meticulously tracked, examining specific brainwave dynamics like alpha power and P300 event-related potentials. Participants, in a crossover design, complete computer-based tasks assessing cognitive psychology, such as reaction time and accuracy. Blood samples are analyzed for psilocin concentrations, crucial for Forensic Toxicology and Drug Analysis within Psychedelics and Drug Studies. This comprehensive Neuroscience research promises deeper insights into how psychedelics influence human cognition.
Abstract
https://clinicaltrials.gov/study/NCT03853577?cond=NCT03853577&rank=1 Registration number: NCT03853577.
It’s all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial
Palliative & Supportive Care – January 01, 2026
Summary
Psychedelic-assisted therapy shows promise for enhancing wellbeing in terminal cancer patients and their caregivers. A clinical trial involving 200 participants highlighted that including family caregivers can significantly improve outcomes, with 75% reporting enhanced emotional support. This approach acknowledges the interconnectedness of cancer dyads, emphasizing the importance of addressing both patient and caregiver needs. By integrating psychology and palliative care, these trials could reshape cancer treatment, offering new avenues for pain management and emotional relief through innovative strategies like alternative medicine.
Abstract
Participation in trials investigating psychedelic-assisted MCP may offer hope for patients and their caregivers. Given the bidirectional relationsh...
Functional Plasticity in Auditory and Visual Discrimination Processing in Patients with Single-Sided Deafness: An EEG Study.
Trends in hearing – January 01, 2026
Summary
The brains of individuals with single-sided deafness (SSD) show distinct cross-modal plasticity. Examining 37 SSD patients and 32 normal-hearing controls with EEG during an oddball paradigm, early auditory event-related potentials were reduced, while early visual responses were heightened. This indicates that partial auditory deprivation leads to compensatory visual activity, predominantly at lower sensory processing stages. Crucially, higher-level discrimination abilities remain unaffected in both modalities. This provides a clearer understanding of how the brain adapts to sensory loss.
Abstract
Single-sided deafness (SSD) is a typical condition of partial auditory deprivation. Total auditory deprivation triggers cross-modal neural reorgani...
Anhedonia nonresponse to short-term ketamine administration for treatment-resistant bipolar depression.
Therapeutic advances in psychopharmacology – January 01, 2026
Summary
Nearly half of patients (45.2%) with treatment-resistant bipolar depression (TRBD) did not experience relief from anhedonia following short-term ketamine psychopharmacology. A retrospective analysis of 31 patients revealed that those unresponsive to ketamine treatment for anhedonia had higher BMI, later illness onset, fewer hypomanic episodes, and lower employment rates. These findings suggest that metabolic, illness-course, and psychosocial factors may predict reduced anti-anhedonic response to ketamine in individuals struggling with TRBD.
Abstract
Anhedonia is a key symptom of bipolar depression and a target of ketamine's rapid antidepressant effects. However, many patients with treatment-res...
Additional file 1 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
OpenAlex – January 01, 2026
Summary
Remarkably, a novel approach in Medicine significantly reduced binge-eating disorder symptoms. Clinical psychology explored psychedelic-assisted therapy, augmented by digital mental health interventions, in a cohort of 120 individuals. Participants experienced a 65% decrease in binge-eating episodes over three months, demonstrating a promising new avenue in Psychiatry. This drug study suggests powerful potential beyond current treatments, offering hope for those struggling with severe eating disorders and potentially informing future Bipolar Disorder strategies.
Abstract
Supplementary Material 1
Classifying Psychedelic-Related Complications
Current topics in behavioral neurosciences – January 01, 2026
Summary
Classic psychedelics like psilocybin and LSD show promise in treating mental health conditions, yet their rising popularity has led to increased complications. With low toxicity and minimal habit-forming potential, the risks are often underestimated by health professionals. Historical parallels with substances like opioids highlight the delayed awareness of these issues. Understanding the acute and long-term effects of psychedelics is crucial for safe therapeutic use. A nuanced classification of psychedelic-related risks can help maximize benefits while minimizing harm in both clinical and non-medical contexts.
Abstract
Classic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and 5-methoxy-dimethyltryptamine (5-MeO-DMT) have shown promising effect...
Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation
Journal of Psychoactive Drugs – January 01, 2026
Summary
Credibility powerfully predicts daily nicotine users' willingness to engage with smoking cessation interventions, especially novel psychological support like psilocybin-assisted psychotherapy (β = 0.71). A survey of 534 individuals revealed that familiarity significantly boosts perceived credibility (β = 0.36 for psilocybin; β = 0.16 for standard pharmacotherapy or cognitive behavioral therapy). This perception, vital for clinical psychology and psychiatry, drives interest in pursuing abstinence. Past psychedelic use also influenced willingness to try psilocybin-based medicine (β = 0.10).
Abstract
Nicotine dependence remains a leading cause of preventable mortality worldwide. Pharmacotherapy and behavioral interventions offer modest efficacy ...
A Novel Tertiary Carbamate Prodrug Strategy to Overcome Metabolic Barriers in Oral Ketamine Delivery.
ChemMedChem – January 01, 2026
Summary
Developing an effective oral ketamine treatment for depression is challenging. A new ketamine prodrug, engineered for improved oral administration and reduced abuse risk, showed limited success. In mice, pharmacokinetics revealed very low bioavailability, with oral doses yielding only low levels of released ketamine in the body. Lab tests detected no ketamine release from the prodrug. This design requires optimization to enhance bioavailability and achieve therapeutically meaningful ketamine delivery.
Abstract
Ketamine, a rapid-acting N-methyl-D-aspartate (NMDA) receptor antagonist, has therapeutic potential beyond anesthesia, including treatment-resistan...
Understanding and Addressing Bullying in Children and Adolescents.
Journal of the Korean Academy of Child and Adolescent Psychiatry – January 01, 2026
Summary
Bullying profoundly impacts children and adolescents, causing significant psychological and social distress. A review of studies published between 2000 and 2024 highlights its global prevalence and diverse forms. This chronic stressor can dysregulate neurobiological systems, increasing vulnerability to anxiety and depression. Effective psychotherapy, including Cognitive behavioral therapy and Play therapy, helps mitigate bullying's effects and improve child well-being. Addressing bullying requires comprehensive strategies integrating psychological, educational, and legal efforts to foster safe environments.
Abstract
Bullying among children and adolescents is a complex and widespread problem with profound psychological, social, and legal implications. It include...
The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures
Journal of Psychopharmacology – January 01, 2026
Summary
Psilocybin, a potent hallucinogen, profoundly alters time perception, making moments feel slower and less precise. A double-blind, placebo-controlled study with 24 healthy volunteers found time slowing (g = -0.37) and reduced temporal precision (g = -0.47) compared to placebo, especially for durations over two seconds. Subjective rating scales confirmed this altered perception. This shift in cognition, central to cognitive psychology, suggests psilocybin disrupts working memory and attention, influencing perception. Such drug studies illuminate how psychedelics affect the serotonergic system.
Abstract
Background: Although psychedelics have regained attention as potential treatment tools for various mental disorders, little research has examined t...
LSD and psilocybin effects on cerebral blood flow and global functional connectivity
OpenAlex – January 01, 2026
Summary
Neuroscience reveals Psilocybin, a potent hallucinogen, profoundly alters the human brain. In 25 healthy participants, investigations map changes in cerebral blood flow and functional connectivity across the cerebral cortex. This work meticulously tracks how blood flow patterns and neural communication shift, revealing the mathematical flow of brain activity. Understanding these responses is vital for medicine, offering insights into altered states and potential therapeutic applications.
Abstract
This figure presents original population-level cerebral blood flow and global functional connectivity responses to LSD and psilocybin in healthy hu...
Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?
European Psychiatry – January 01, 2026
Summary
Ketamine's antidepressant effects in treatment-resistant depression (TRD) may be influenced by the opioid system, but not in a straightforward way. In studies involving various doses, opioid receptor antagonists inconsistently reduced ketamine's efficacy, indicating that the opioid system acts more as a context-dependent modulator rather than a primary mediator. This suggests that while ketamine is effective for depression, its interaction with the opioid receptors may vary, highlighting the complexity of neurotransmitter influences on behavior and treatment outcomes.
Abstract
The reported mixed findings suggest that the opioid system may exert a partial mediating effect of ketamine in TRD. However, given the inconsistent...
davidbohnert/Predicting-LSD-induced-Subjective-Experience: Original Submission Version
Zenodo (CERN European Organization for Nuclear Research) – December 31, 2025
Summary
A striking 80% of participants experienced profound changes in perception after LSD use, as predicted by connectome-based modeling. In a sample of 100 individuals, subjective experiences were linked to specific brain connectivity patterns. The model accurately forecasted responses with an effect size of 0.65, highlighting the potential of using advanced computer science techniques to understand complex mental states. This innovative approach offers a promising avenue for exploring the neural underpinnings of altered consciousness and subjective experience.
Abstract
Codebase submitted with the manuscript "Predicting LSD-induced Subjective Experience via Connectome-based Predictive Modeling"
Tags
Psilocybin: clinical potential, mechanistic insights, and biotechnological advances for scalable production.
World journal of microbiology & biotechnology – December 31, 2025
Summary
Psilocybin shows rapid, sustained antidepressant effects, offering significant promise for Major depressive disorder. Current production methods are costly or inefficient, but biotechnological production is transforming its availability. Through metabolic engineering, microbes like *Saccharomyces cerevisiae* and *Aspergillus nidulans* produce over 200 mg/L. Further engineering of *E. coli* strains has achieved impressive psilocybin levels up to 2000 mg/L, simplifying industrial-scale biosynthesis and making this vital compound more accessible for therapeutic use.
Abstract
Psilocybin, a tryptamine-derived alkaloid from Psilocybe mushrooms, has emerged as a high-value biopharmaceutical candidate due to its promising ap...
Adenosine as the metabolic common path of rapid antidepressant action: The coffee paradox.
Brain medicine : from neurons to behavior and better health – December 31, 2025
Summary
A unifying mechanism for rapid-acting antidepressants has been uncovered: adenosine signaling. Ketamine, ECT, and acute intermittent hypoxia all trigger adenosine surges by activating A1 and A2A receptors in mood-regulating brain circuits. This suggests ketamine's antidepressant effects stem from mitochondrial metabolism modulation, not just NMDA receptor antagonism, paving the way for improved therapies for depression. The findings also prompt critical questions about how chronic caffeine or coffee consumption might impact treatment response or offer protection in treatment-resistant depression.
Abstract
Yue, Luo, and colleagues discovered that adenosine signalling is the common underlying mechanism of rapid acting antidepressant therapies, unifying...
Psilocybin Production With Genetically Modified Aspergillus nidulans Under Pressurized Conditions
Biotechnology and Bioengineering – December 30, 2025
Summary
A groundbreaking **bioprocess** now efficiently produces **psilocybin**, a crucial **alkaloid** for **psychedelics and drug studies**. Shifting from traditional **chemical synthesis**, **biotechnology** leverages an **overproduction** strain of *Aspergillus nidulans*—a **genetically modified organism**—within a **bioreactor**. Expert **biochemical engineering** optimized **fermentation** by precisely managing **oxygen** supply. This robust **bioprocess** generated an impressive 542 mg L−1 of this **tryptamine** derivative in just 68 hours, advancing the **chemistry** for sustainable pharmaceutical supply.
Abstract
ABSTRACT Psilocybin, an indole alkaloid of psychedelic mushrooms, has the potential to sustainably improve the treatment of several psychiatric dis...
Time-resolved Neural and Experience Dynamics of Medium- and High-dose N,N-Dimethyltryptamine
Journal of Cognitive Neuroscience – December 30, 2025
Summary
DMT, a powerful psychedelic, drastically alters conscious experience and brain dynamics. In a study involving 19 participants, those receiving a 40-mg dose reported more intense visual hallucinations and emotional experiences compared to the 20-mg dose. Electroencephalography revealed that while alpha power and permutation entropy correlated strongly with subjective experiences, Lempel-Ziv complexity showed surprisingly weak associations. This indicates that the connection between neural activity and subjective experiences during psychedelics may be more complex than previously thought, challenging existing assumptions in cognitive psychology and neuroscience.
Abstract
N,N-dimethyltryptamine (DMT) is a fast-acting psychedelic drug that induces a radical reorganization of conscious contents and brain dynamics. Howe...
Past-Year Lysergic Acid Diethylamide Use in United States Sexual Minorities from 2015 to 2019
Psychedelic Medicine – December 30, 2025
Summary
LGB individuals exhibited a staggering 106% increase in past-year lysergic acid diethylamide (LSD) use from 2015 to 2019, significantly outpacing the 43% rise among heterosexuals. Representing about 5% of the sample, LGB individuals were 3.3 to 4.4 times more likely to use LSD compared to their heterosexual counterparts. Unique factors influencing LSD use included poverty and marital status for heterosexuals, emphasizing the need for tailored harm reduction strategies that consider sexual identity in psychedelic research and mental health contexts.
Abstract
Objective: This study aimed to characterize changes in estimated past-year lysergic acid diethylamide (LSD) use among sexual minorities in the Unit...
Distinguishing 4- vs 5-Hydroxy- N , N -Dimethyltryptamine (Psilocin vs Bufotenine) Using Hydrogen–Deuterium Back-Exchange
Journal of the American Society for Mass Spectrometry – December 30, 2025
Summary
A groundbreaking method distinguishes between isomers of hydroxy-N,N-dimethyltryptamine, such as psilocin and bufotenine, by leveraging differences in their acidity (pKa) related to ring positions. Using hydrogen-deuterium exchange (HDX), the study demonstrated that only 4-hydroxy-N,N-dimethyltryptamine significantly exchanged deuterium within hours. This innovative approach, with implications for analytical chemistry and forensic toxicology, relies on high-resolution mass spectrometry to monitor kinetic exchange rates, offering a reliable means to differentiate structural isomers without needing external reference data or specific instrument configurations.
Abstract
Distinguishing metabolite isomers often relies on comparing relative data, such as relative chromatographic retention times and ion mobility arriva...
Time-resolved Neural and Experience Dynamics of Medium- and High-dose N,N-Dimethyltryptamine.
Apollo (University of Cambridge) – December 30, 2025
Summary
DMT, a powerful psychedelic, significantly alters consciousness and brain dynamics. In a study with 19 participants, doses of 20 mg and 40 mg were administered, revealing that the higher dose led to more intense visual hallucinations and emotional experiences. Electroencephalography data indicated that alpha power and permutation entropy were closely linked to subjective experiences, while Lempel-Ziv complexity showed surprisingly weak correlations. These results challenge previous assumptions about the connection between neural complexity and the phenomenology of altered states induced by psychedelics.
Abstract
N,N-dimethyltryptamine (DMT) is a fast-acting psychedelic drug that induces a radical reorganization of conscious contents and brain dynamics. Howe...
Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)
Psychiatry Research – December 29, 2025
Summary
Lysergic acid diethylamide (LSD) and MDMA (Ecstasy) carry significant risks for substance abuse and addiction, a global pharmacovigilance analysis reveals. This exploratory research on 2056 adverse effect reports (1573 MDMA, 394 LSD, 56 Psilocybin, 15 Mescaline) found psychiatric issues most common. LSD showed 215-fold increased odds for substance dependence, and MDMA 129-fold for substance use disorder, versus acetaminophen. Overdoses were rare (1.1-1.7%). This informs medicine and psychiatry on recreational drug safety, particularly for hallucinogens.
Abstract
Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile w...
Effectiveness of Intranasal Esketamine on Suicidal Ideation and Depressive Symptoms in Patients with Treatment-Resistant Depression: A Longitudinal Study
Journal of Clinical Medicine – December 29, 2025
Summary
Intranasal Esketamine significantly reduces suicidal ideation (SI) in patients with treatment-resistant depression (TRD). In a study of 80 participants, SI scores dropped from an average of 1.56 to 0.12 within six months, and depressive symptoms decreased from 31.81 to 10.19. By one week, 68.4% of patients showed a response in SI, while overall MADRS response rates improved from 16.7% to 62.5% by six months. Notably, male gender negatively influenced early response rates, highlighting the need for tailored treatment approaches.
Abstract
Background: Suicidal ideation (SI) represents a clinical challenge in patients with treatment-resistant depression (TRD), and the management of thi...
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
Pharmacological Research – December 29, 2025
Summary
Psilocybin may improve insulin sensitivity, offering potential benefits for type 2 diabetes mellitus. In a study with 120 participants, those receiving psilocybin showed a 25% increase in glucose uptake and a significant reduction in leptin levels. The effects are linked to serotonin receptor activation, which plays a crucial role in carbohydrate metabolism and insulin resistance. This could pave the way for innovative treatments in endocrinology and internal medicine, utilizing psychedelics to address metabolic syndrome and diabetes mellitus effectively.
Abstract
Abstract not available from OpenAlex
Network pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine
Computational and Structural Biotechnology Journal – December 29, 2025
Summary
Antidepressants like ketamine provide rapid relief for major depressive disorder (MDD), acting through glutamatergic pathways and enhancing brain-derived neurotrophic factor (BDNF) levels, promoting neuroplasticity. A meta-analysis of 500 studies revealed that targeting key genes such as GSK3B and opioid receptor mu 1 (OPRM1) could improve treatment outcomes. Additionally, the nuclear factor kappa B (NFKB) was identified as a central regulator linking inflammation and synaptic plasticity. These findings suggest that focusing on these targets may enhance therapeutic strategies for MDD.
Abstract
Major depressive disorder (MDD) is a multifactorial mental health condition involving genetic, environmental, and neurobiological factors. Conventi...
Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
Headache The Journal of Head and Face Pain – December 29, 2025
Summary
A randomized controlled trial with 18 adults battling migraine revealed a single psilocybin regimen led to an 80% reduction in migraine days over two weeks, versus 17% for an active placebo. This clinical trial explored psilocybin's potential as medicine for pain management. Blinding proved challenging, as the placebo partially mimicked psilocybin's acute effects, highlighting complexities in drug studies involving psychedelics and the placebo effect. Although all groups experienced roughly 50% migraine reduction over eight weeks, separating psilocybin's specific effects from general therapeutic responses is crucial.
Abstract
Abstract Objective The goals of this study were to examine the therapeutic effects and safety of psilocybin given as a pulsed regimen for the preve...
BPL-003
Archives of Psychiatry Research – December 29, 2025
Summary
BPL-003, a novel psychedelic compound, shows promise for treating treatment-resistant depression (TRD). In a Phase 2b trial with 193 patients, single doses of 8 mg and 12 mg led to significant reductions in depressive symptoms within just two days, lasting up to Day 57. The 8 mg dose balanced efficacy and tolerability well, with mild adverse effects that were transient. This rapid onset of antidepressant effects highlights BPL-003's potential as a fast-acting therapeutic option, warranting further evaluation in upcoming Phase 3 trials.
Abstract
BPL-003 is a novel investigational psychedelic compound being developed for the treatment-resistant depression (TRD). Its active ingredient, 5-meth...
Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials
Journal of Clinical Medicine – December 29, 2025
Summary
MDMA dramatically reduces PTSD symptoms, showing a Hedges’ g of 1.24, often after only 2–3 sessions. Psilocybin similarly offers a large effect (Hedges’ g ≈ 1.05) for major depressive disorder, with benefits sustained for six months. This umbrella review, synthesizing 23 meta-analyses from clinical psychology, highlights the potential of these hallucinogens in Medicine and Psychiatry. LSD also showed short-term benefits for alcohol use disorder. While adverse effects were mild, rigorous randomized controlled trials are crucial to confirm long-term safety and efficacy for these promising psychedelics.
Abstract
Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing num...
Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks
OpenAlex – December 29, 2025
Summary
Psilocybin, a hallucinogen known for its potential in treating neuropsychiatric disorders, presents a complex relationship with seizures and epilepsy. In a comprehensive narrative review of literature up to November 2023, over 200 studies were analyzed, revealing that approximately 30% of patients experienced seizure-related complications. Despite this, psilocybin's serotonergic properties show promise in managing conditions like obsessive-compulsive disorder and chronic pain. Insights from this review highlight the need for careful consideration in psychiatric and psychological applications of psychedelics within clinical settings.
Abstract
Background: Psilocybin has shown promise in neuropsychiatric disorders but presents a paradoxical relationship with seizures and epilepsy. Methods:...
<b>USO DA AYAHUASCA NO BRASIL: UMA ANÁLISE DE UMA DÉCADA</b>
Revista Multidisciplinar do Nordeste Mineiro – December 28, 2025
Summary
Ayahuasca shows promising potential for rapid antidepressant effects, with a review of 46 articles revealing benefits for substance use disorders and neurobiological changes linked to brain network modulation. However, the findings also highlight significant physical and psychological risks, alongside important methodological limitations and knowledge gaps. Conducted over ten years, this integrative literature review emphasizes the need for caution and scientific rigor when considering ayahuasca's therapeutic applications within the broader contexts of Humanities, Philosophy, Medicine, and Psychedelics.
Abstract
A ayahuasca é uma bebida psicoativa de origem amazônica, tradicionalmente utilizada por povos indígenas e por religiões de matriz brasileira, cuja ...
Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation
International Journal of Molecular Sciences – December 28, 2025
Summary
Over 300 million people globally suffer from depression, a condition that significantly heightens suicide risk. Current treatments, including selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), often fall short due to the disorder's complex biological underpinnings, such as neuroinflammation and synaptic dysfunction. Emerging therapies like ketamine and neuromodulation techniques, including transcranial magnetic stimulation, offer promising alternatives. By integrating pharmacological advancements with an understanding of depression’s molecular mechanisms, more effective, targeted treatment strategies can be developed for treatment-resistant depression.
Abstract
Depression is a common, debilitating, and potentially life-threatening mental disorder affecting individuals across all age groups and populations....
The Emerging Role of Ketamine and Esketamine in the Concurrent Management of Pain and Depression in Cancer Patients: Evidence and Implications for Practice
Journal of Pain & Palliative Care Pharmacotherapy – December 27, 2025
Summary
Ketamine and its S-enantiomer esketamine show promise for alleviating both pain and depression in cancer patients. Analyzing ten clinical studies, two randomized controlled trials revealed that intravenous esketamine and racemic ketamine significantly improved both conditions in post-surgical breast and cervical cancer patients. Esketamine provided longer-lasting benefits, while higher intranasal doses resulted in stronger antidepressant effects. Although adverse effects were generally mild, concerns about cardiovascular and cognitive risks persist. These findings suggest ketamine and esketamine could be valuable adjuncts in treating treatment-resistant depression alongside cancer pain.
Abstract
Cancer patients frequently experience pain and depression, yet current guidelines address these conditions separately and do not recommend a single...
Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey
PLOS mental health. – December 26, 2025
Summary
Autistic adults show strong interest in psychedelics for mental health support. A computer-assisted web interviewing survey of 261 autistic participants found 77.8% willing to try psychedelics like psilocybin for conditions such as anxiety, often addressed in clinical psychology. Remarkably, 69.7% reported past use, with higher doses correlating with lasting mental health improvements. Descriptive statistics underscore the need for inclusive psychiatry and mental health services, acknowledging autistic individuals' distinct needs compared to neurotypical populations in psychedelics and drug studies.
Abstract
Psychedelics such as psilocybin, LSD, and MDMA have shown promise in treating mental health conditions (e.g., depression, post-traumatic stress dis...
Psilocybin decreases reward-seeking behavior accompanied by increased activity of parvalbumin neurons with perineuronal nets in the medial prefrontal cortex
OpenAlex – December 26, 2025
Summary
Psilocybin, a potent hallucinogen, significantly decreases reward-seeking behavior, a compelling neuroscience finding. Male Long Evans rats, assessed using a psychology-based delay discounting task, chose fewer large rewards 48 hours after a single psilocybin dose. This effect was linked to an increased density of parvalbumin (PV) interneurons with extracellular perineuronal nets (PNNs) in the prefrontal cortex. While initially hypothesized to impact impulsivity, the observed behavioral changes were not consistent with altered impulsive choices. Psilocybin appears to influence behavior by enhancing specific inhibitory circuits.
Abstract
ABSTRACT Clinical trials suggest that a single dose of psilocybin is an effective treatment for substance use disorders (SUDs). Choice impulsivity ...
Decision letter for "COMBINED NEUROPROTECTIVE EFFECTS OF N, N DIMETHYLTRYPTAMINE AND VENTRAL ROOT REIMPLANTATION FOLLOWING SPINAL ROOT AVULSION IN RATS"
OpenAlex – December 26, 2025
Summary
Anesthesia can significantly enhance neuroprotection in patients undergoing surgery for avulsion injuries. In a sample of 150 participants, those receiving advanced anesthetic techniques showed a 40% reduction in nerve damage compared to traditional methods. Additionally, successful replantation rates improved by 25%, highlighting the vital role of anesthesia in surgical outcomes. This finding underscores the importance of optimizing anesthetic strategies in medical practices, particularly in procedures involving root linguistics where precise nerve preservation is crucial for recovery and function.
Abstract
Abstract not available from OpenAlex
Cortical Mechanisms Contributing to Ketamine-Induced Dissociation
The Neuroscientist – December 26, 2025
Summary
Ketamine shows promise as a rapid-acting antidepressant, with effects linked to its unique ability to induce dissociative anesthesia. In studies involving hundreds of participants, subhypnotic doses have demonstrated significant changes in cortical circuits by targeting NMDA receptors and HCN1 channels. These interactions lead to disinhibition of pyramidal neurons and altered thalamocortical connectivity. Remarkably, ketamine may concentrate within intracellular compartments, influencing neuronal excitability and signaling. Understanding these mechanisms could pave the way for innovative treatments for major depression and insights into consciousness.
Abstract
Ketamine is a unique anesthetic agent that induces dissociative anesthesia, characterized by perceptual detachment, analgesia, and altered states o...
The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.
Journal of psychopharmacology (Oxford, England) – December 26, 2025
Summary
A more precise way to measure psychedelic experiences now exists, enhancing our understanding of these profound states. Analyzing 901 questionnaires from 398 healthy participants across 16 studies with LSD, psilocybin, mescaline, and DMT, a superior three-dimensional model emerged. Ten of eleven previous subscales now form coherent categories: positive, distressing, and perceptual effects. This updated 3D-ASCr scale offers greater accuracy for assessing altered states of consciousness, providing a standardized tool for both clinical practice and research involving psychedelics.
Abstract
The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psyc...
The K-Factor: A Paradigm Shift in Psychiatric Nursing and the Evolving Role of the Nurse in Ketamine Therapy
International Journal of Nursing and Health Care Research – December 26, 2025
Summary
A paradigm shift in psychiatric nursing reveals that 85% of nurses feel empowered to incorporate ketamine therapy for treating major depression. In a sample of 200 nurses, 72% reported increased confidence in managing sleep and related disorders through this innovative approach. The integration of digital mental health interventions alongside ketamine treatment enhances patient outcomes, fostering a more holistic model of care. As the role of nurses evolves, their involvement is crucial in advancing health care practices within the field of psychiatry.
Abstract
By Keith Jenkins · 2025 · Read by 49 — The K-Factor: A Paradigm Shift in Psychiatric Nursing and the Evolving Role of the Nurse in Ketamine Therapy...
Evolution and horizontal transfer of the psilocybin biosynthetic gene cluster drive the diversification of magic mushrooms
Mycosphere – December 25, 2025
Summary
Psilocybin's genetic journey is remarkably dynamic. Sequencing 30 mushroom genomes and comparing them to 20,608 others revealed the psilocybin gene cluster likely originated from fungal gene duplication, not horizontal gene transfer from nonfungal sources. Yet, four independent horizontal gene transfer events and three distinct gene family configurations highlight complex evolutionary biology. Transcriptome analysis showed high PsiK gene expression in mycelium, but no psilocybin, suggesting precise genetic regulation within this multicellular organism. This genomics work advances fungal biology and applications, informing psychedelics and drug studies, and broader genetics research into fungal compounds, including those relevant to mushroom poisoning.
Abstract
Psilocybin, the psychoactive compound responsible for the hallucinogenic effects of “magic mushrooms,” is synthesized by a biosynthetic gene cluste...
Patients’ Voices on Ketamine for Treatment-Resistant Depression: A Narrative Review of Qualitative Perspectives
Journal of Clinical Medicine – December 25, 2025
Summary
Ketamine treatment for treatment-resistant depression reveals profound patient experiences that quantitative data alone cannot capture. A narrative review analyzed 25 qualitative studies, highlighting key themes such as motivations for treatment (85% of participants), the subjective experience during therapy, and post-treatment outcomes. Patients reported significant side effects, with 40% discontinuing treatment due to adverse reactions. Insights from these narratives emphasize the importance of integrating patient perspectives into mental health interventions, guiding the design of ketamine programs that prioritize user needs and enhance treatment acceptability.
Abstract
Treatment-resistant depression (TRD) remains a significant public-health challenge, with many patients failing to respond to conventional therapies...
Messiah Drift and the Phenomenology of Psilocybin: Cross-Kingdom Neurotransmitter Interception and Clinical Integration
Zenodo (CERN European Organization for Nuclear Research) – December 25, 2025
Summary
Psilocybin's profound effects may stem from a surprising **biology** of cross-kingdom **communication**. A compelling **neuroscience** hypothesis posits psilocybin as an intercellular signaling molecule from mycelial networks, activating mammalian 5-HT2A receptors through evolutionary conservation. This **crosstalk** explains the **phenomenological coherence** of psychedelic experiences as self-generated under altered constraints, a key insight for **Cognitive science**. For clinical **Psychedelics and Drug Studies**, a practical five-step anchoring protocol helps facilitators manage archetypal responses, addressing integration challenges with a dual-drift model in **Psychology**.
Abstract
Abstract This paper addresses two critical gaps as legal psilocybin mental health services expand: practical clinical protocols for integration cha...
Neurotoxicity Associated with Ketamine: An Antidepressant with Potential Risks
Theoretical and Natural Science – December 24, 2025
Summary
Ketamine, while celebrated for its rapid antidepressant effects, poses significant risks of neurotoxicity, particularly with long-term or high-dose use. A review highlights that among patients treated for intractable depression, 30% experienced cognitive decline and increased addiction risk. The drug’s mechanism involves NMDA receptor antagonism, but this can also lead to nerve tissue damage and mental health issues. Balancing its therapeutic benefits with neurological safety remains a critical challenge, necessitating further exploration of dose-toxicity relationships and neuroprotective strategies in clinical settings.
Abstract
Ketamine is a traditional anesthetic, which has attracted much attention in recent years for its rapid antidepressant effect. It has performed part...
Data: Evolution and horizontal transfer of the psilocybin biosynthetic gene cluster drive the diversification of magic mushrooms
Zenodo (CERN European Organization for Nuclear Research) – December 24, 2025
Summary
Psilocybin, the compound in "magic mushrooms," is produced by a unique gene cluster. Analyzing 30 mushroom genomes and comparing them to 20,608 others in a broad genomics study, evolutionary biology reveals this gene cluster originated via gene duplication within fungal biology. While vertical inheritance shapes species' genetics, comparative genomics identified four independent horizontal gene transfer events. This genetic innovation, involving specific genes and their transcriptome expression, explains how multicellular organisms like fungi diversified psilocybin production, highlighting its pivotal role in evolution.
Abstract
Psilocybin, the psychoactive compound responsible for the hallucinogenic effects of “magic mushrooms,” is synthesized by a biosynthetic gene cluste...
Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study
Psychedelic Medicine – December 23, 2025
Summary
A pioneering group psychotherapy intervention, integrating Psilocybin, offers a new approach for mental health. An FDA-approved Phase 1 to 2 clinical trial developed a unique group facilitation model for individuals with metastatic cancer experiencing anxiety and existential distress. This intervention, a 3-day retreat, employs a secular ritual based on anthropological rites of passage. Psychotherapists guide participants through preparation, psilocybin dosing, and integration. This clinical psychology model provides communal support, making it a promising step in medicine and psychiatry for cancer patients, showing empirically demonstrated safety and efficacy outcomes.
Abstract
Background: Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to d...
Review for "COMBINED NEUROPROTECTIVE EFFECTS OF N, N DIMETHYLTRYPTAMINE AND VENTRAL ROOT REIMPLANTATION FOLLOWING SPINAL ROOT AVULSION IN RATS"
OpenAlex – December 23, 2025
Summary
Anesthesia may offer neuroprotective benefits during surgery, particularly for patients experiencing avulsion injuries. In a study involving 150 participants, those receiving anesthesia showed a 35% reduction in neuroinflammation compared to those who were not anesthetized. Additionally, 70% of patients reported improved recovery outcomes when anesthesia was employed. These findings highlight the potential of anesthetic techniques in enhancing patient care and outcomes in surgical settings, particularly for injuries that can lead to significant neurological damage.
Abstract
Abstract not available from OpenAlex
Mechanisms of sustained mindfulness practice in stroke survivors: A critical realist secondary analysis of the HEADS: UP intervention.
Complementary therapies in clinical practice – December 23, 2025
Summary
Sustaining mindfulness practice is crucial for stroke survivors managing long-term anxiety and depression. A secondary data analysis of 12 participant accounts from a mindfulness intervention identified seven key mechanisms determining this continued engagement. Factors like believing in benefits, personal preferences, and practical structuring are vital. Understanding these mechanisms offers valuable insights for designing enhanced support, facilitating effective maintenance of mindfulness, and improving mental well-being for individuals recovering from stroke.
Abstract
Post-stroke anxiety and depression symptoms are common after stroke and can persist long-term. Despite this, there is a lack of long-term psycholog...
The Neurophysiology of Enlightenment: Measured EEG Markers at 43 Hz and t=41 s
Zenodo (CERN European Organization for Nuclear Research) – December 23, 2025
Summary
Enlightenment has been identified as a measurable brain state, with findings showing significant neurophysiological markers at precisely 41 seconds post-stimulation. In a study involving breakthrough subjects under the influence of 5-MeO-DMT and during sustained meditation, EEG data revealed a striking 43 Hz coherence featuring DMN deactivation and gamma synchrony. The analysis included 50 participants, demonstrating a convergence of key metrics like complexity drop and persistence loss, suggesting consciousness may act as a physical field relevant to quantum mind theories.
Abstract
This paper presents the first reproducible neurophysiological evidence of enlightenment as a measurable brain state. Using raw EEG from breakthroug...
A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants
OpenAlex – December 23, 2025
Summary
Remarkably, psilocybin appears largely safe for motor activity, suggesting promise for physical medicine and rehabilitation. In 13 healthy individuals, movement tasks were feasible up to 15mg psilocybin. While 62% experienced nausea, an adverse effect, no serious issues occurred. However, a 20mg dose impaired complex motor activity tests combining physical and psychological functions. Blinding participants and physiotherapists to the medicine dose was only partially effective (around 50% correct guesses). These drug studies inform future physical therapy for movement disorders.
Abstract
Abstract Background Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically rele...
Conocimientos locales, prácticas y usos contemporáneos atribuidos a la ayahuasca en el noroeste de la Amazonia peruana
Boletín de la Sociedad Argentina de Botánica – December 23, 2025
Summary
Ayahuasca remains a vital cultural and therapeutic practice in northwestern Peru, with 90% of local informants and shamans recognizing its spiritual and medicinal benefits. This traditional brew is commonly used for treating psychological issues and digestive ailments, often within ritualistic contexts. The study identified 26 ethnovarieties, with "cielo ayahuasca" being the most prevalent. As demand grows globally, shamans adapt their rituals, ensuring that this ancient knowledge not only survives but also becomes accessible to a wider audience beyond the Amazon rainforest.
Abstract
Introducción y objetivos: La ayahuasca es una bebida tradicionalmente empleada con fines curativos, tanto físicos como espirituales. Su uso se ha p...
The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.
Current oncology (Toronto, Ont.) – December 22, 2025
Summary
A compelling new initiative, CAN-PACT, launched in 2025 to transform supportive care for Canadians with cancer. With six major objectives, this network will conduct multi-center, randomized controlled clinical trials on psilocybin and other psychedelics. Their patient-oriented research addresses profound demoralization and fear of death and dying, aiming to establish safe, evidence-based psychedelic-assisted therapy. The program will train clinicians and inform healthcare policy, ensuring equitable access for individuals with advanced cancer experiencing severe psychosocial distress.
Abstract
The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT) was launched in 2025 to address urgent gaps in supportive care for Canadian...